BAT 5906
Alternative Names: BAT-5906Latest Information Update: 25 Apr 2024
At a glance
- Originator Bio-Thera Solutions
- Class Eye disorder therapies; Monoclonal antibodies
- Mechanism of Action Vascular endothelial growth factors inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Wet age-related macular degeneration
- Phase II Diabetic macular oedema
Most Recent Events
- 06 Nov 2023 Bio-Thera Solutions completes a phase I/II trial in Diabetic macular oedema in China (Intravitreous) (NCT04772105)
- 26 Sep 2022 Phase-II clinical trials in Diabetic macular oedema in China (Intravitreous)
- 26 Sep 2022 Bio-Thera Solutions plans a phase III trial for Wet age-related macular degeneration in China (Bio-Thera Solutions pipeline, September 2022), (NCT05439629)